INTS
Intensity Therapeutics, Inc.
Set alert
3.40 USD +0.06 +1.80%
3.21 Day range 3.46
3.14 52-week range 33.00
- YTD
- -66.83%
- 1 year
- -89.70%
- Open
- 3.40
- Prev close
- 3.34
- Mkt cap
- 11.10M
- Vol
- 16.12K
- Avg vol
- 25.19K
- EPS
- -3.89
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.21
- High
- 3.46
- Forward P/E
- -1.66
- Beta
- 0.00
- Short ratio
- 3.05
- Inst. own
- 12.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 2.90
- 200-d avg
- 4.10
- 1y target
- 10.00
Key statistics
- Market cap
- 29.56M
- Enterprise value
- 37.55M
- Trailing P/E
- 0.00
- Forward P/E
- -1.66
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.04
- EPS (TTM)
- -1.07
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 9.66M
- Total cash
- 6.32M
- Total debt
- 151.00K
- Return on equity
- -147.23%
- Shares outstanding
- 15.10M
- Short % of float
- 0.48%
- 50-day average
- 2.90
- 200-day average
- 4.10
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 10.00 +194.1% upside
Now 3.40
- Target (low)
- 4.00
- Target (mean)
- 10.00
- Target (high)
- 16.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate 0.00.
Financials — quick view
INTS Revenue — quarterly 0
INTS Net income — quarterly -3.01M
INTS EPS — quarterly -1.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.27 | -0.25 | +0.02 | +7.41% |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.36 | — | — |
| Mar 14, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | -0.17 | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 31, 2024 | HC Wainwright & Co. | init | — | Buy |
| Jul 11, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| May 16, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Mar 21, 2024 | Benchmark | reit | Speculative Buy | Speculative Buy |
| Nov 14, 2023 | Benchmark | reit | Speculative Buy | Speculative Buy |
About Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs in the United States. Its lead product candidate includes INT230-6, which is in human clinical studies for the treatment of refractory solid tumors, such as soft tissue sarcoma which is in phase 3 trails; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- intensitytherapeutics.com
News
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026
- Intensity Therapeutics To Present Data For First Seven Participants In Group A In INVINCIBLE-4 Trial In ePoster By The Swiss Cancer Institute At ESMO 2026 Virtual Congress Platform
- Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript
- Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
Your note
Sign in to keep a note on INTS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| WESOLOWSKI JOHN CPA | Officer | Conversion of Exercise of derivative security | Jun 4, 2024 | 6,691 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sapient Capital LLC | 6.69% | 1,010,753 | 1.98M | Sep 29, 2024 |
| Vanguard Group Inc | 1.38% | 208,886 | 408.85K | Sep 29, 2024 |
| Brown Advisory Inc. | 0.98% | 148,109 | 289.89K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.43% | 64,349 | 125.95K | Sep 29, 2024 |
| Sigma Planning Corp | 0.32% | 47,744 | 93.45K | Sep 29, 2024 |
| Mesirow Financial Investment Management, Inc. | 0.29% | 44,177 | 86.47K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.11% | 168,299 | 329.41K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.27% | 40,587 | 79.44K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.23% | 34,522 | 67.57K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.13% | 20,123 | 39.39K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 9,421 | 18.44K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 8,141 | 15.93K | Oct 30, 2024 |